Why do I need it? I am not at risk! Public perceptions towards the pandemic (H1N1) 2009 vaccine.
BACKGROUND
On the 30th September 2009, the pandemic (H1N1) 2009 influenza vaccine was made available to adults and children aged 10 years and over, in Australia. Acceptance of a novel vaccine is influenced by perceptions of risk including risk of infection, risk of death or severe illness and risk of serious vaccine side-effects. We surveyed a sample of residents from Sydney, Australia to ascertain their risk perception, attitudes towards the pandemic and willingness to accept the pandemic (H1N1) 2009 influenza vaccine.


METHODS
We sampled residents using a cross-sectional intercept design during the WHO Phase 6. Members of the public were approached in shopping and pedestrian malls to undertake the survey during September and October 2009. The survey measured perceived risk, seriousness of disease, recent behavioural changes, likely acceptance of the pandemic (H1N1) 2009 vaccine and issues relating to uptake and perceived safety.


RESULTS
Of the 627 respondents, the majority felt that they had a "very low to low" (332/627, 52.9%) risk of acquiring H1N1. 24.5% (154/627) of respondents believed that the disease would "very seriously or extremely" affect their health. Nearly half (305/627, 48.6%) reported that in response to the "swine flu" outbreak they had undertaken one or more of the investigated behavioural changes. Overall, the self-reported likelihood of accepting vaccination against novel H1N1 was 54.7% (343/627).


CONCLUSIONS
While, most participants did not believe they were at high risk of acquiring pandemic H1N1 2009, over half of the sample indicated that they would accept the vaccine. Participants who were vaccinated against the seasonal influenza were more likely to receive the H1N1 vaccine. Concerns about safety, the possibility of side effects and the vaccine development process need to be addressed.
Seale
Holly
H
School of Public Health and Community Medicine, Faculty of Medicine, The University of New South Wales, Sydney, Australia. h.seale@unsw.edu.au
Heywood
Anita E
AE
McLaws
Mary-Louise
ML
Ward
Kirsten F
KF
Lowbridge
Chris P
CP
Van
Debbie
D
MacIntyre
C Raina
CR
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001315:Australia / Q000453:epidemiology; D003430:Cross-Sectional Studies; D004196:Disease Outbreaks / Q000517:prevention & control*; D005260:Female; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology*; D007251:Influenza, Human / Q000453:epidemiology* / Q000517:prevention & control* / Q000821:virology; D008297:Male; D008875:Middle Aged; D010342:Patient Acceptance of Health Care / Q000706:statistics & numerical data*; D055815:Young Adult
D007252:Influenza Vaccines
MMWR Morb Mortal Wkly Rep. 2009 May 1;58(16):431-3
19407737
Med J Aust. 2009 Sep 7;191(5):267-9
19740048
Euro Surveill. 2009 Dec 10;14(49):
20003909
BMJ. 2009 Oct 27;339:b4164
19861377
Vaccine. 2009 Sep 25;27(42):5732-4
19679219
N Engl J Med. 2009 Dec 31;361(27):2591-4
19940287
N Engl J Med. 2009 Dec 17;361(25):2414-23
19846844
N Engl J Med. 2009 Dec 17;361(25):2405-13
19745216
MMWR Morb Mortal Wkly Rep. 2009 Apr 24;58(15):400-2
19390508
Clin Infect Dis. 2005 Jun 15;40(12):1713-20
15909256
Am J Infect Control. 2009 Jun;37(5):371-380
19121548
BMJ. 2009 Jul 02;339:b2651
19574308
Med J Aust. 2010 Jan 4;192(1):33-6
20047546